関連文献

Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.

Hypertens Res . 34: 935-941, 2011.PubMed

Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy.

Nephrol Dial Transplant. 26(7): 2127-2137, 2011.PubMed

Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.

Nephrol Dial Transplant. 26(11): 3465-3473, 2011.PubMed

Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients.

Diabetes Care. 34(3): 691-696, 2011.PubMed

Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.

Eur J Clin Invest. 40(2): 95-102, 2010.PubMed

Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients.

Diabetes Care. 33(6): 1320-1324, 2010.PubMed

Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.

Am J Med Sci. 339(2): 157-163, 2010.PubMed

Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.

Kidney Blood Press Res. 33(3): 213-220, 2010.PubMed

Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.

Eur J Clin Invest. 40(9): 790-796, 2010.PubMed

Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.

Nephron Clin Pract. 112(3): c148-156, 2009.PubMed